PROCLAIM 3期试验中局部晚期非小细胞肺癌同步放化疗的放射治疗质量保证(RTQA)
PROCLAIM 3期试验评估两种同步放化疗方案,对所有患者强制实施放射治疗质量保证(RTQA),554例中40例出现重大方案偏离;在收治≥2例重大偏离患者的中心(n=86),患者中位总生存期(21.1个月 vs 29.8个月;风险比1.442)和无进展生存期(7.3个月 vs 11.3个月;风险比1.345)均低于无重大偏离中心的患者。
要点
- 554例中40例存在重大RTQA偏离,涉及28个中心,7个中心有≥2例重大偏离患者。
- 收治≥2例重大偏离患者的中心(n=86)中位总生存期21.1个月 vs 29.8个月(风险比1.442),无进展生存期7.3个月 vs 11.3个月(风险比1.345)。
- 多因素分析中总生存期差异仍显著,作者认为该结果属于假设生成性质。
核心结论
- PROCLAIM研究中治疗方案重大偏离不常见,可能反映了强制RTQA的作用。
- 需要更复杂放化疗计划的患者中RTQA偏离更频繁。
- 收治多例重大偏离患者的中心观察到的较差结局属于假设生成性质。
研究设计与样本
- 研究于2008年至2014年开展,为评估两种不同放化疗方案的PROCLAIM 3期试验。
- 所有患者均强制进行照射计划审查,每个中心首例入组患者在放疗开始前实时审查,另随机抽取20%患者实时审查,其余为非实时审查。
- RTQA评估标准包括计划靶区覆盖、剂量均匀性、接受≥20 Gy的肺体积以及脊髓最大点剂量。
主要发现
- 554例患者中40例存在重大RTQA偏离,涉及28个中心,其中7个中心有≥2例重大偏离患者。
- 重大偏离患者中IIIB期疾病和较大计划靶区更常见。
- 收治<6例或>15例患者的中心重大偏离更常见。
- 收治≥2例重大偏离患者的中心(n=86)中位总生存期为21.1个月 vs 29.8个月(风险比1.442),中位无进展生存期为7.3个月 vs 11.3个月(风险比1.345),均低于无重大偏离中心的患者。
- 多因素分析中总生存期差异仍显著。
关键数值与推荐
- RTQA评估标准包括计划靶区覆盖、剂量均匀性、接受≥20 Gy的肺体积和脊髓最大点剂量。
- 重大RTQA偏离定义为违反上述RTQA标准。
临床怎么用
- 原文未据此给出推荐。
局限性
- 收治多例重大偏离患者的中心观察到的较差结局属于假设生成性质。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Chemoradiation therapy trials of different tumors, including lung cancer, have shown a correlation between protocol deviations and adverse outcomes. Radiation therapy quality assurance (RTQA) was mandated for all patients treated in the PROCLAIM trial evaluating 2 different chemoradiation therapy regimens. The RTQA results were evaluated from the PROCLAIM study, and the impact of irradiation deviations on efficacy outcomes was investigated. METHODS AND MATERIALS: The study was conducted from 2008 to 2014. Review of the irradiation plan was mandated for all patients. Real-time review was performed prior to irradiation start for the first enrolled patient at each site and randomly in 20% of additional patients, with non-real-time review in the remainder. The RTQA criteria evaluated included planning target volume coverage, dose homogeneity, volume of lung receiving ≥20 Gy, and maximum point dose to spinal cord. RESULTS: Major RTQA violations occurred in 40 of 554 patients, treated at 28 sites. Seven sites treated ≥2 patients with major violations. Stage IIIB disease and larger planning target volume were observed more frequently in patients with major violations. Major violations were more prevalent in sites treating either <6 patients or >15 patients. Patients treated at sites enrolling ≥2 patients with major violations (n = 86) had lower median overall survival (21.1 months vs 29.8 months; hazard ratio, 1.442) and progression-free survival (7.3 months vs 11.3 months; hazard ratio, 1.345) than patients treated at sites without major violations. These findings remained significant for overall survival on multivariate analysis. CONCLUSIONS: Major violations in treatment plans were uncommon in the PROCLAIM study, possibly reflecting mandatory RTQA. The RTQA violations were more frequent in patients requiring more complex chemoradiation therapy plans. Poorer observed outcomes at centers with multiple major violations are hypothesis generating.
引用
- Brade AM, Wenz F, Koppe F, et al. Radiation Therapy Quality Assurance (RTQA) of Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer in the PROCLAIM Phase 3 Trial. Int J Radiat Oncol Biol Phys. 2018. PMID: 29976505. doi:10.1016/j.ijrobp.2018.04.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。